Larotrectinib Capsules 25mg

Description

Larotrectinib 25mgis a prescription medicine that is used to treat adults and children with solid tumors (cancer) that: are caused by certain abnormal NTRK genes and have spread or if surgery to remove their cancer is likely to cause severe complications, and there is no acceptable treatment option or the cancer grew or spread on other treatment. Your healthcare provider will perform a test to make sure that Larotrectinib is right for you. It is not known if Larotrectinib is safe and effective in children younger than 1 month of age. What are the possible side effects of Larotrectinib? Larotrectinib may cause serious side effects, including: Nervous system problems. Tell your healthcare provider if you develop any symptoms such as confusion, difficulty speaking, dizziness, coordination problems, tingling, numbness, or burning sensation in your hands and feet. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop Larotrectinib if you develop symptoms of a nervous system problem with Larotrectinib. Liver problems. Your healthcare provider will do blood tests to check your liver function during treatment with Larotrectinib. Tell your healthcare provider right away if you develop symptoms of liver problems including: loss of appetite, nausea or vomiting, or pain on the upper right side of your stomach area. Your healthcare provider may temporarily stop treatment, decrease your dose, or permanently stop Larotrectinib if you develop liver problems with Larotrectinib. The most common side effects of Larotrectinib include: tiredness nausea dizziness vomiting cough constipation diarrhea Larotrectinib may affect fertility in females and may affect your ability to become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all the possible side effects with Larotrectinib. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. DESCRIPTION Larotrectinib is a kinase inhibitor. Larotrectinib (larotrectinib) capsules and oral solution are formulated using larotrectinib sulfate. The molecular formula for larotrectinib sulfate is C21H24F2N6O6S and the molecular weight is 526.51 g/mol for the sulfate salt and 428.44 g/mol for the free base. The chemical name is (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)-1- pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide sulfate. Larotrectinib sulfate has the following chemical structure: Larotrectinib® (larotrectinib) Structural Formula – Illustration Larotrectinib sulfate is an off-white to pinkish yellow solid that is not hygroscopic. The aqueous solubility of larotrectinib at 37°C is pH dependent (very soluble at pH 1.0 and freely soluble at pH 6.8, according to USP descriptive terms of solubility). Larotrectinib (larotrectinib) capsules and oral solution are for oral use. Each capsule contains 25 mg or 100 mg larotrectinib (30.7 mg and 123 mg larotrectinib sulfate, respectively) in a hard gelatin capsule. The capsule is composed of gelatin, titanium dioxide, and edible ink. The oral solution contains 20 mg/mL larotrectinib (24.6 mg/mL larotrectinib sulfate) and the following inactive ingredients: purified water, hydroxypropyl betadex, sucrose, glycerin, sorbitol, citric acid, sodium phosphate, sodium citrate dihydrate, propylene glycol and flavoring. Preserved with methylparaben and potassium sorbate.